Stay updated with breaking news from Lilly India. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
American pharma major Eli Lilly has decided to withdraw insulin Glargine, sold under the brand name of Basaglar KwikPen, from the Indian market.
/PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will supply its active pharmaceutical ingredient (API) for human insulin at a reduced price to International...
Lilly will transfer its rights in India to sell, promote and distribute the aforesaid two Lilly Diabetes products – Humalog and Trulicity to Cipla
Lilly said that the existing operating model for its other products would remain unaltered. The idea is to leverage Cipla's strong local footprint.
Eli Lilly, Cipla enter into strategic partnership in India